Rhumbline Advisers lifted its stake in Cambrex Co. (NYSE:CBM) by 15.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 75,657 shares of the biotechnology company’s stock after purchasing an additional 10,177 shares during the quarter. Rhumbline Advisers’ holdings in Cambrex were worth $3,632,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in CBM. Boston Partners boosted its holdings in shares of Cambrex by 118.5% in the 4th quarter. Boston Partners now owns 709,786 shares of the biotechnology company’s stock worth $34,069,000 after purchasing an additional 384,897 shares during the period. Peregrine Capital Management LLC purchased a new position in shares of Cambrex in the 4th quarter worth approximately $9,780,000. Brown Advisory Inc. boosted its holdings in shares of Cambrex by 1,638.7% in the 3rd quarter. Brown Advisory Inc. now owns 161,577 shares of the biotechnology company’s stock worth $8,888,000 after purchasing an additional 152,284 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Cambrex by 117.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 231,931 shares of the biotechnology company’s stock worth $12,721,000 after purchasing an additional 125,062 shares during the period. Finally, Summit Creek Advisors LLC purchased a new position in shares of Cambrex in the 4th quarter worth approximately $5,182,000.
Cambrex Co. (NYSE:CBM) opened at $55.15 on Thursday. Cambrex Co. has a 1-year low of $42.55 and a 1-year high of $62.95. The stock has a market capitalization of $1,844.35, a price-to-earnings ratio of 17.22, a P/E/G ratio of 1.36 and a beta of 2.38.
Cambrex (NYSE:CBM) last posted its quarterly earnings data on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.17. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The company had revenue of $182.28 million during the quarter, compared to analysts’ expectations of $181.39 million. During the same quarter in the previous year, the business earned $1.23 EPS. Cambrex’s revenue was up 2.5% compared to the same quarter last year. analysts forecast that Cambrex Co. will post 2.76 earnings per share for the current year.
CBM has been the subject of a number of recent research reports. Zacks Investment Research upgraded Cambrex from a “strong sell” rating to a “hold” rating in a report on Monday, January 15th. Longbow Research cut Cambrex from a “buy” rating to a “neutral” rating in a report on Wednesday, February 14th. Finally, William Blair initiated coverage on Cambrex in a report on Tuesday, January 16th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $60.00.
TRADEMARK VIOLATION WARNING: “Rhumbline Advisers Buys 10,177 Shares of Cambrex Co. (CBM)” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.thelincolnianonline.com/2018/03/15/rhumbline-advisers-buys-10177-shares-of-cambrex-co-cbm.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.